Photodynamic Therapy for Corneal Neovascularization Using Polymeric Micelles Encapsulating Dendrimer Porphyrins

Sugisaki, Kenji; Usui, Tomohiro; Nishiyama, Nobuhiro; Jang, Woo Dong; Yanagi, Yasuo; Yamagami, Satoru; Amano, Shiro; Kataoka, Kazunori

doi:10.1167/iovs.07-0389

Cited by 49 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…By now, most of these nanostrategies are used in many areas of PDT. For example, dendrimer porphyrin encapsulation into polymeric micelles [58] is used for the treatment of corneal neovascularization, a major sight-threatening condition caused by inflammation, infections and degenerative disorders [69,70,71]. Visudyne ® the first photodynamic drug approved for treatment of age related macular degeneration (AMD) is used to reduce the risk of vision loss.…”

Section: 'Nano' Strategies For Photosensitizermentioning

confidence: 99%

Nanodrug applications in photodynamic therapy

Paszko

Ehrhardt

Senge

et al. 2011

Photodiagnosis and Photodynamic Therapy

326

215

View full text Add to dashboard Cite

SummaryPhotodynamic therapy (PDT) has developed over last century and is now becoming a more widely used medical tool having gained regulatory approval for the treatment of various diseases such as cancer and macular degeneration. It is a two-step technique in which delivery of a photosensitizing drug is followed by irradiation of light. Activated photosensitizers transfer energy to molecular oxygen which results in generation of reactive oxygen species which in turn cause cells apoptosis or necrosis. Although this modality has significantly improved quality of life and survival time for many cancer patients it still offers significant potential for further improvement. In addition to the development of new PDT drugs, the use of nanosized carriers for photosensitizers is a promising approach which might improve the efficiency of photodynamic activity and which can overcome many side effects associated with classic photodynamic therapy. This review aims at highlighting the different types of nanomedical approaches currently used in PDT and outlines future trends and limitations of nanodelivery of photosensitizers. PDT -photodynamic therapy; PGA -poly(glycolic acid); PGLA -poly(D,L-lactide-coglycolide); PLA -poly(lactic acid); PS -photosensitizer; PEG -polyethylene glycol; ALA  aminolevulinic acid; m-THPC  5,10,15,20-tetra-(m-hydroxyphenyl)chlorine; m-THPP  meso-tetra(p-hydroxyphenyl); PpIX  protoporphyrin; Hp  hematoporphyrin; Pc4  silicon phthalocyanine; Ig  immunoglobulin; Tf  transferrin; TfR  transferrin receptor; VEGF  vascular endothelial growth factor; EPR  enhanced permeability and retention effect; FRET  fluorescence resonance energy transfer; MRI  magnetic resonance imaging; RES  reticuloendothelial system; ROS  reactive oxygen species; NP  nanoparticle; ND -nanodiamonds; SNP  silica nanoparticle; AMD  age-related macular degeneration; CNV  choroidal neovascularization; PTT  photothermal therapy;

show abstract

Section: 'Nano' Strategies For Photosensitizermentioning

confidence: 99%

Nanodrug applications in photodynamic therapy

Paszko

Ehrhardt

Senge

et al. 2011

Photodiagnosis and Photodynamic Therapy

326

215

View full text Add to dashboard Cite

show abstract

“…The use of antisense oligonucleotides has already moved into a Phase II clinical trial with studies of gene signal (GS)-101, an antisense oligonucleotide that inhibits the expression of IRS-1 and is designed only to target currently growing neovessels. In this randomized, double-blind, multicenter, dosedetermining study, four groups of 10 patients were treated with three doses of GS-101 (43,86, and 172 mg/day total) or placebo administered twice daily in eye drops. The results showed that GS-101 eye drops were well tolerated at an optimal dose of 86mg/day, which specifically inhibited and promoted the regression of NV, providing an effective and noninvasive approach for the treatment of active corneal angiogenesis.…”

Section: Anti-vegf Treatmentsmentioning

confidence: 99%

Nanotechnology in Corneal Neovascularization Therapy—A Review

Gonzalez

Loza

Han

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Nanotechnology is an up-and-coming branch of science that studies and designs materials with at least one dimension sized from 1-100 nm. These nanomaterials have unique functions at the cellular, atomic, and molecular levels.1 The term ''nanotechnology'' was first coined in 1974. 2 Since then, it has evolved dramatically and now consists of distinct and independent scientific fields. Nanotechnology is a highly studied topic of interest, as nanoparticles can be applied to various fields ranging from medicine and pharmacology, to chemistry and agriculture, to environmental science and consumer goods. 3 The rapidly evolving field of nanomedicine incorporates nanotechnology with medical applications, seeking to give rise to new diagnostic means, treatments, and tools. Over the past two decades, numerous studies that underscore the successful fusion of nanotechnology with novel medical applications have emerged. This has given rise to promising new therapies for a variety of diseases, especially cancer. It is becoming abundantly clear that nanotechnology has found a place in the medical field by providing new and more efficient ways to deliver treatment. Ophthalmology can also stand to benefit significantly from the advances in nanotechnology research. As it relates to the eye, research in the nanomedicine field has been particularly focused on developing various treatments to prevent and/or reduce corneal neovascularization among other ophthalmologic disorders. This review article aims to provide an overview of corneal neovascularization, currently available treatments, and where nanotechnology comes into play.

show abstract

“…MRI) [56]. Thus, they can be used for oral, transdermal, ocular and intravenous deliveries [60,61]. Moreover, dendrimers have shown that they can easily cross cell barriers by both paracellular and transcellular pathways [56].…”

Section: Dendrimersmentioning

confidence: 99%